nach oben

04.05.2024 | News

New guideline of the European Medicines Agency (EMA) on the clinical investigation of medicinal products in the treatment and prevention of diabetes mellitus

verfasst von: Bart Van der Schueren, Patrick Vrijlandt, Andrew Thomson, Heidi Janssen, Kristina Dunder

Einloggen, um Zugang zu erhalten

Excerpt

The European Medicines Agency (EMA)’s revised guideline on the clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus took effect on 1 January 2024, replacing the previous guideline from 2012 [1, 2]. The guideline is intended to address the current European Union regulatory position on the main topics of importance for the clinical development of new medicinal products in the treatment or prevention of type 1 and type 2 diabetes. One of the main reasons for revising the previous guideline was to update the section on cardiovascular safety, which was addressed in greater detail in the 2016 reflection paper on the assessment of the cardiovascular safety profile of medicinal products [3]. However, the diabetes field has evolved rapidly over the last decade and the revision also presented an opportunity to address other topics that, in the view of EMA or other stakeholders, warranted clarification. …

European Medicines Agency (2024) Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-or-prevention-diabetes-mellitus-revision-2_en.pdf. Accessed 21 April 2024

European Medicines Agency (2012) Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-or-prevention-diabetes-mellitus-revision-1_en.pdf. Accessed 21 April 2024

European Medicines Agency (2016) Reflection paper on assessment of cardiovascular safety profile of medicinal products. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-assessment-cardiovascular-safety-profile-medicinal-products_en.pdf. Accessed 21 April 2024

Wilson LM, Castle JR (2020) Recent advances in insulin therapy. Diabetes Technol Ther 22(12):929–936. https://doi.org/10.1089/dia.2020.0065CrossRefPubMedPubMedCentral

Battelino T, Conget I, Olsen B et al (2012) The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 55(12):3155–3162. https://doi.org/10.1007/s00125-012-2708-9CrossRefPubMedPubMedCentral

Palmer SC, Tendal B, Mustafa RA et al (2021) Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 372:m4573. https://doi.org/10.1136/bmj.m4573CrossRefPubMedPubMedCentral

Davies MJ, Aroda VR, Collins BS et al (2022) Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 65(12):1925–1966. https://doi.org/10.1007/s00125-022-05787-2CrossRefPubMedPubMedCentral

European Medicines Agency (2016) Concept paper on the need for revision of the guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-need-revision-guideline-clinical-investigation-medicinal-products-treatment-or-prevention-diabetes-mellitus_en.pdf. Accessed 21 April 2024

European Medicines Agency (2018) Draft guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-or-prevention-diabetes-mellitus-revision-2_en.pdf. Accessed 21 April 2024

10.

European Medicines Agency (2022) Reflection paper on data required in confirmatory studies of medicinal products for the treatment of type 2 diabetes. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-data-required-confirmatory-studies-medicinal-products-treatment-type-2-diabetes-revision-2_en.pdf. Accessed 21 April 2024

11.

Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329(14):977–986. https://doi.org/10.1056/NEJM199309303291401CrossRef

12.

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359(15):1577–1589. https://doi.org/10.1056/NEJMoa0806470CrossRefPubMed

13.

Heller SR, Buse JB, Ratner R et al (2020) Redefining hypoglycemia in clinical trials: validation of definitions recently adopted by the American Diabetes Association/European Association for the Study of Diabetes. Diabetes Care 43(2):398–404. https://doi.org/10.2337/dc18-2361CrossRefPubMed

14.

International Hypoglycaemia Study Group (2017) Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 40(1):155–157. https://doi.org/10.2337/dc16-2215CrossRef

15.

European Medicines Agency (2020) ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e9-r1-addendum-estimands-and-sensitivity-analysis-clinical-trials-guideline-statistical-principles-clinical-trials-step-5_en.pdf. Accessed 21 April 2024

16.

Perkins BA, Rosenstock J, Skyler JS et al (2019) Exploring patient preferences for adjunct-to-insulin therapy in type 1 diabetes. Diabetes Care 42(9):1716–1723. https://doi.org/10.2337/dc19-0548CrossRefPubMedPubMedCentral

17.

ElSayed NA, Aleppo G, Aroda VR et al (2023) 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes-2023. Diabetes Care 46(Suppl 1):S19–S40. https://doi.org/10.2337/dc23-S002CrossRefPubMed

Titel: New guideline of the European Medicines Agency (EMA) on the clinical investigation of medicinal products in the treatment and prevention of diabetes mellitus
verfasst von: Bart Van der Schueren
Patrick Vrijlandt
Andrew Thomson
Heidi Janssen
Kristina Dunder
Publikationsdatum: 04.05.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-024-06162-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen